RxSight (RXST) Short term Debt (2022 - 2023)
RxSight (RXST) posted Short term Debt of $5.2 million for Q2 2023, up 186.96% on a QoQ basis from $1.8 million in Q3 2022, and up 186.96% year-over-year from $1.8 million in Q2 2022.
RxSight (RXST) Short term Debt (2022 - 2023) Analysis & Trends
RxSight's Short term Debt history runs 2 years deep, the most recent figure standing at $5.2 million for Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | RxSight | 221.81 Mn | -196.39 Mn | 23.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 5.22 Mn |
| Sep 30, 2022 | 1.82 Mn |
| Jun 30, 2022 | 1.82 Mn |